Program
Methotrexate
Also written as “methotrexate”, “Methotrexate (MTX)” and “MTX”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Gout · Arthritis, Psoriatic · Arthritis, Juvenile, led by 24 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 360 open or running | phase 4since Apr 18, 2007 | Oct 21, 2005 | none ahead |
| Bristol-Myers Squibb | 91 open or running | phase 4since Sep 4, 2015 | Jul 19, 2005 | none ahead |
| Pfizer | 80 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| AbbVie | 60 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | none ahead |
| Johnson & Johnson | 60 open or running | phase 3since Dec 11, 2005 | Dec 11, 2005 | none ahead |
| Aldeyra Therapeutics | 31 open or running | phase 3since Oct 21, 2019 | Oct 21, 2019 | Dec 2029phase 3 · NCT07402876 |
| AstraZeneca | 30 open or running | phase 4since Aug 23, 2023 | Sep 16, 2005 | none ahead |
| medac | 31 open or running | phase 3since Jan 11, 2024 | May 14, 2013 | Nov 2026phase 3 · NCT06239311 |
| Merck | 30 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Halozyme Therapeutics | 20 open or running | phase 2since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Amneal Pharmaceuticals | 10 open or running | phase 1since Sep 15, 2016 | Sep 15, 2016 | none ahead |
| Azidus Brasil | 10 open or running | phase 2since Apr 15, 2020 | Apr 15, 2020 | none ahead |
| Biocad | 10 open or running | phase 3since Apr 4, 2016 | Apr 4, 2016 | none ahead |
| Biogen | 10 open or running | phase 4since May 27, 2005 | May 27, 2005 | none ahead |
| Celltrion | 10 open or running | phase 1since May 22, 2013 | May 22, 2013 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since Dec 4, 2012 | Dec 4, 2012 | none ahead |
| forsight-vision4 | 10 open or running | phase 2since Apr 24, 2014 | Apr 24, 2014 | none ahead |
| gema-biotech-s-a | 10 open or running | phase 3since Apr 21, 2016 | Apr 21, 2016 | none ahead |
| jeffrey-j-crowley-md | 10 open or running | phase 3since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| mediquest-therapeutics | 10 open or running | phase 2since Apr 22, 2008 | Apr 22, 2008 | none ahead |
| nordic-pharma-sas | 10 open or running | phase 3since Sep 16, 2015 | Sep 16, 2015 | none ahead |
| prof-kristian-reich | 10 open or running | phase 3since Jul 26, 2016 | Jul 26, 2016 | none ahead |
| Sanofi | 10 open or running | phase 3since Nov 13, 2014 | Nov 13, 2014 | none ahead |
| xbiotech-inc | 11 open or running | phase 2since Aug 22, 2024 | Aug 22, 2024 | Jan 15, 2027phase 2 · NCT06590090 |
Also a collaborator on its studies: Lakefront Biotherapeutics NV, Roche Pharma, Regeneron Pharmaceuticals, Integrated Therapeutics Group, Accutest Research Laboratories (I) Pvt., PPD DEVELOPMENT, LP, UCB, Immunex, Basilea Pharmaceutica International, Tanabe Pharma, Astellas Pharma US and Eisai.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Aug 18, 2009.
- May 15, 2017Phase 3 study in Arthritis, RheumatoidHoffmann-La Roche · NCT03155347 · 340 enrolled · China
- Jul 12, 2017jeffrey-j-crowley-md's first study: phase 3 study in PsoriasisNew to jeffrey-j-crowley-mdjeffrey-j-crowley-md · NCT03217734 · 56 enrolled · United States
- Oct 21, 2019Aldeyra Therapeutics's first study: phase 3 study in Vitreoretinopathy, ProliferativeNew to Aldeyra TherapeuticsAldeyra Therapeutics · NCT04136366 · 106 enrolled · United States
- Feb 11, 2020Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT04268394 · 48 enrolled · United Kingdom
- Apr 15, 2020Azidus Brasil's first study: phase 2 study in COVID-19New to Azidus BrasilAzidus Brasil · NCT04352465 · 42 enrolled · Brazil
- May 28, 2021Phase 3 study in Arthritis, RheumatoidBristol-Myers Squibb · NCT04909801 · 338 enrolled · United States, Argentina, Australia and more
- Mar 28, 2022Phase 2 study in Retinitis PigmentosaAldeyra Therapeutics · NCT05392179 · 8 enrolled · United States
- Jun 30, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05445440 · 30 enrolled · United States
- Nov 7, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05615012 · 76 enrolled · United States
- Aug 23, 2023Phase 4 study in HypophosphatasiaAstraZeneca · NCT06015750
- Jan 11, 2024Phase 3 study in Moderate to Severe Atopic Dermatitismedac · NCT06239311 · 277 planned · Czechia, France, Italy and more
- Aug 22, 2024xbiotech-inc's first study: phase 2 study in Arthritis, RheumatoidNew to xbiotech-incxbiotech-inc · NCT06590090 · 108 planned
- Jan 29, 2026Phase 3 study in Primary Vitreoretinal LymphomaAldeyra Therapeutics · NCT07402876 · 20 planned · United States
- Nov 16, 2026Primary completion moved from 2026-12 to 2029-12Date moved laterphase 3 · +36 months · NCT07402876
Ahead
- Nov 2026Primary completion: phase 3 study in Moderate to Severe Atopic Dermatitismedac · NCT06239311
- Jan 15, 2027Primary completion: phase 2 study in Arthritis, Rheumatoidxbiotech-inc · NCT06590090
- Dec 2029Primary completion: phase 3 study in Primary Vitreoretinal LymphomaAldeyra Therapeutics · NCT07402876
TargetBeta
“Dihydrofolate reductase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Other programs on DHFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| pralatrexaterule | Aurobindo Pharma | phase 4 | 19 |
Studies
The newest 60 of 93 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07402876Primary Vitreoretinal Lymphoma · United States | 3 | Recruiting | Aldeyra Therapeutics | Dec 2029 | 20 |
| NCT06590090Arthritis, Rheumatoid | 2 | Not yet recruiting | xbiotech-inc | Jan 15, 2027 | 108 |
| NCT06239311Moderate to Severe Atopic Dermatitis · Czechia, France, Italy and more | 3 | Recruiting | medac | Nov 2026 | 277 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05615012Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Dec 13, 2023 | 76 |
| NCT05445440Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 17, 2022 | 30 |
| NCT05392179Retinitis Pigmentosa · United States | 2 | Completed | Aldeyra Therapeutics | Jun 23, 2023 | 8 |
| NCT04909801Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jun 14, 2023 | 338 |
| NCT04352465COVID-19 · Brazil | 2 | UNKNOWN | Azidus Brasil | Jun 30, 2020 | 42 |
| NCT04268394Healthy Volunteer · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jun 2, 2021 | 48 |
| NCT04136366Vitreoretinopathy, Proliferative · United States | 3 | Completed | Aldeyra Therapeutics | Jun 14, 2022 | 106 |
| NCT03217734Psoriasis · United States | 3 | Completed | jeffrey-j-crowley-md | Dec 31, 2018 | 56 |
| NCT03155347Arthritis, Rheumatoid · China | 3 | Completed | Hoffmann-La Roche | Aug 8, 2022 | 340 |
| NCT02940561Psoriasis · India | 1 | UNKNOWN | Amneal Pharmaceuticals | Oct 2016 | 48 |
| NCT02902861Psoriasis Vulgaris · Germany | 3 | Completed | prof-kristian-reich | Sep 2014 | 120 |
| NCT02831855Arthritis, Rheumatoid · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 19, 2018 | 694 |
| NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more | 4 | Completed | AbbVie | Sep 23, 2019 | 246 |
| NCT03332719Arthritis, Rheumatoid · Argentina | 3 | Completed | gema-biotech-s-a | Mar 2017 | 168 |
| NCT02744196Arthritis, Rheumatoid | 3 | Completed | Biocad | Feb 2017 | 159 |
| NCT02699710Healthy Volunteer · United Kingdom | 1 | Completed | Hoffmann-La Roche | May 26, 2016 | 50 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Aug 2002 | 161 |
| NCT02553018Arthritis, Rheumatoid · France | 3 | Completed | nordic-pharma-sas | Aug 2017 | 278 |
| NCT02557100Arthritis, Rheumatoid · United States, Canada, Mexico | 4 | Completed | Bristol-Myers Squibb | Mar 28, 2019 | 80 |
| NCT02504268Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 16, 2017 | 994 |
| NCT02293902Arthritis, Rheumatoid · Japan | 3 | Completed | Sanofi | Oct 2016 | 243 |
| NCT02277444Arthritis, Juvenile · United States, Argentina, Brazil and more | 3 | Completed | Johnson & Johnson | Jul 9, 2018 | 130 |
| NCT02196701Psoriasis | 3 | Completed | AbbVie | Mar 17, 2017 | 46 |
| NCT02187055Rhematoid Arthritis · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Dec 2016 | 1,152 |
| NCT02125266Uveitis, Posterior · United States | 2 | Terminated | forsight-vision4 | Oct 2014 | 7 |
| NCT02097173Psoriasis · United States | 1 | Completed | medac | Oct 2013 | 35 |
| NCT02006706Arthritis, Rheumatoid · Serbia | 3 | Completed | Hoffmann-La Roche | Nov 23, 2007 | 15 |
| NCT01987479Arthritis, Rheumatoid · Netherlands | 3 | Completed | Hoffmann-La Roche | May 26, 2016 | 150 |
| NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 401 |
| NCT01941095Arthritis, Rheumatoid · Greece | 3 | Completed | Hoffmann-La Roche | Jul 10, 2016 | 100 |
| NCT01878318Arthritis, Rheumatoid | 4 | Withdrawn | Hoffmann-La Roche | Jun 2015 | 0 |
| NCT01873443Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Oct 2014 | 87 |
| NCT01871961Arthritis, Rheumatoid · United States | 1 | Completed | medac | Feb 2013 | 105 |
| NCT01855789Arthritis, Rheumatoid · United States | 3 | Completed | Hoffmann-La Roche | Oct 14, 2016 | 718 |
| NCT01746680Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jun 2015 | 111 |
| NCT01737944Arthritis, Rheumatoid · United States | 2 | Completed | Halozyme Therapeutics | May 2011 | 38 |
| NCT01661140Arthritis, Rheumatoid · United Kingdom | 4 | Terminated | Hoffmann-La Roche | Feb 2015 | 427 |
| NCT01645280Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more | 2 | Completed | Johnson & Johnson | Dec 2013 | 274 |
| NCT01618968Arthritis, Rheumatoid · United States | 2 | Completed | Halozyme Therapeutics | Aug 2012 | 49 |
| NCT01587989Arthritis, Rheumatoid · Austria | 3 | Completed | Hoffmann-La Roche | Feb 2014 | 77 |
| NCT01399697Arthritis, Rheumatoid · Spain | 4 | Completed | Hoffmann-La Roche | May 2014 | 261 |
| NCT01353859Arthritis, Rheumatoid · Indonesia | 3 | Completed | Hoffmann-La Roche | Jul 2012 | 39 |
| NCT01347983Arthritis, Rheumatoid · Taiwan | 3 | Completed | Hoffmann-La Roche | Mar 2013 | 72 |
| NCT01258712Arthritis, Rheumatoid · Taiwan | 3 | Completed | Hoffmann-La Roche | Oct 2012 | 86 |
| NCT01235507Arthritis, Rheumatoid · Bosnia and Herzegovina | 3 | Completed | Hoffmann-La Roche | Dec 2012 | 71 |
| NCT01185301Arthritis, Rheumatoid · United States, Argentina, Austria and more | 3 | Completed | AbbVie | Sep 2012 | 395 |
| NCT01185288Arthritis, Rheumatoid · United States, Puerto Rico | 4 | Completed | AbbVie | Jan 2013 | 309 |
| NCT01163747Arthritis, Rheumatoid · United States | 4 | Completed | Hoffmann-La Roche | Dec 2011 | 91 |
| NCT01142726Arthritis, Rheumatoid · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Sep 2013 | 511 |
| NCT01162421Arthritis, Rheumatoid | 4 | Completed | AbbVie | Jul 2015 | 77 |
| NCT01063062Arthritis, Rheumatoid · Egypt | 3 | Completed | Hoffmann-La Roche | Jan 17, 2011 | 107 |
| NCT01034137Arthritis, Rheumatoid · Netherlands | 3 | Completed | Hoffmann-La Roche | Sep 2014 | 317 |
| NCT01007435Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | May 31, 2012 | 1,162 |
| NCT01000610Arthritis, Rheumatoid · Tunisia | 4 | Completed | Hoffmann-La Roche | May 16, 2012 | 18 |
| NCT00973479Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Mar 2011 | 592 |
| NCT00965653Arthritis, Rheumatoid · Canada, New Zealand, Spain | 1 | Completed | Hoffmann-La Roche | 29 |
How it is read
Names in the registry
- “Methotrexate”, 71 entries
- “methotrexate”, 28 entries
- “Methotrexate (MTX)”, 7 entries
- “MTX”, 4 entries
- “methotrexate (MTX)”, 3 entries
Codes read as this program: ADX2191.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 84 studies
- Psoriasis, 10 studies
- Gout, 8 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.